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Abstract Coenzyme A (CoA-SH), endogenous and drug-de-
rived CoA-derivatives were tested as putative antagonists of
P2Y receptors expressed in Xenopus laevis oocytes, a method
used to determine calcium-activated chloride current, an indica-
tor of the activation of these receptors. CoA-SH antagonized
reversibly and in a concentration-dependent manner the ATP-
gated currents evoked by the human P2Y1 but not the P2Y2
receptor. Palmitoyl-CoA was four-fold more potent than CoA-
SH as an antagonist while palmitoyl-carnitine was inactive,
highlighting the role of the CoA-SH moiety in the antagonism.
The CoA derivatives of nafenopin and cipro¢brate, two clini-
cally relevant hypolipidemic drugs, increased 13 and three-fold
the potency of CoA-SH, respectively. The KBs of nafenopin-
CoA and cipro¢broyl-CoA were 58 and 148 nM, respectively;
the slopes of the Schild plots were unitary. Neither 100 WM
nafenopin nor cipro¢brate alone altered the P2Y1 receptor ac-
tivity. Neither CoA-SH nor cipro¢broyl-CoA antagonized the
rat P2X2 or the P2X4 nucleotide receptors nor interacted with
the 5-HT2A=C receptors. The bulky drug CoA-SH derivatives
identify a hydrophobic pocket, which may serve as a potential
target for novel selective P2Y1 antagonists.
2 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Fibrates such as nafenopin and cipro¢brate have been ex-
tensively used as hypolipidemic drugs. The administration of
these compounds to experimental animals causes a notable
increase in liver peroxisomes. Only recently ¢brates, together
with a variety of endogenous lipophilic compounds, have been
recognized as ligands of the peroxisomal proliferator-activated
receptors (PPARs), which are a group of three nuclear recep-
tor isoforms encoded by di¡erent genes [1]. Fibrates are me-
tabolized either as acyl-CoA derivatives or as glucuronide
conjugates [2,3]. Fatty acids and related lipids are incorpo-
rated to the cell metabolism as acyl-CoAs, reaching intracel-
lular concentrations of 5^160 WM; speci¢c acyl-CoA binding
proteins and fatty acid binding proteins maintain the levels of
free acyl-CoAs in the range of 0.1^200 nM [4]. Upon admin-
istration of these compounds to rodents, the intracellular lev-
els of these drug-CoAs may reach high micromolar concen-
trations [2,4,5], similar to or even higher than those of the
endogenous fatty acyl-CoAs [6].
The P2Y1 receptor was the ¢rst nucleotide receptor cloned
and identi¢ed as a member of the family of receptors coupled
to G proteins [7]. It was initially cloned from chick brain [8]
and immunocytochemical and physiological evidence soon
demonstrated its presence in many regions of the human
CNS, including the hippocampus, cerebellar cortex, caudate
nucleus [9], as well as in the vascular tree [10] and human
platelets [11]. In view of the structural similarity between
ADP/ATP, the endogenous ligands of the P2Y1 receptor,
and coenzyme A (CoA-SH), we investigated whether CoA-
SH and/or its acyl derivatives, either endogenously derived
from fatty acids or derived from the metabolism of drugs
such as the ¢brates, antagonize the P2Y receptors. Nafeno-
pin-CoA and cipro¢broyl-CoA were particularly attractive
since they have a bulky and hydrophobic acyl substitution,
which could help test if bulkiness increases the antagonist
potency of endogenous CoAs. For this purpose, we expressed
the human P2Y1 receptor in Xenopus laevis oocytes and per-
formed electrophysiological protocols in the absence and in
the presence of endogenous and exogenous CoA derivatives.
2. Materials and methods
2.1. Materials
ATP, ADP, acyl-CoAs, acyl-carnitines, CoA-SH, 5-HT, MRS 2179,
sodium salts, and penicillin^streptomycin were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). The synthesis of Naf-CoA, Cip-
CoA and palmitoyl-CoA was performed according to the procedure
of chemical synthesis described by Bronfman et al. [12]. The drug
CoA derivatives were puri¢ed to a single high-performance liquid
chromatography (HPLC) peak following several chromatographic
conditions; enzymatic hydrolysis and mass spectroscopy certi¢ed
pure products. Analytical reagents used to prepare the bu¡ers were
purchased from either Sigma-Aldrich (USA) or Merck (Darmstadt,
Germany).
2.2. Oocyte preparation and expression of receptors
X. laevis oocytes were manually defolliculated and incubated with
collagenase; separate batches of oocytes were injected intranuclearly
with 0.5 ng cDNA coding for the human P2Y1 or the P2Y2 receptor
proteins. Electrophysiological studies were performed as detailed in
Acun‹a-Castillo et al. [13]; ATP-gated currents were recorded follow-
ing a 10 s nucleotide application. Parallel protocols examined the
speci¢city antagonist of the drug CoA derivatives in rat P2X2,
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P2X4, 5-HT2A or 5-HT2C receptor clones. The P2Y and 5-HT2 recep-
tor ligands activate phospholipase C, indirectly promoting the release
of calcium, which activates a chloride current used as an indicator of
receptor activity.
2.3. Antagonism of acyl-CoA and related compounds
To evaluate the relative potency of CoA-SH, Naf-CoA, and other
acyl-CoA derivatives as putative receptor antagonists, ATP dissolved
in Barth’s medium was applied in the absence and later in the pres-
ence of 1 nM^10 WM acyl-CoA derivatives, also dissolved in Barth’s
bu¡er. The compounds were pre-applied for 15 s, followed by a 10 s
co-application with ATP (0.2 WM for the P2Y1 and 3 WM for the
P2Y2 receptors). The mean inhibitory concentration (IC50) was inter-
polated from each curve; results are expressed as the averageOS.E.M.
We assessed the magnitude of the inhibition of the ATP-evoked
currents when 1 WM CoA-SH or 1 WM Cip-CoA were pre-applied
for 0, 15, 30, and 60 s, followed by a 10 s co-application with ATP.
To evaluate the nature of the antagonism, ATP concentration^re-
sponse curve measurements were performed in the absence and later
in the presence of 0.1, 0.3, 1, or 5 WM Naf-CoA or Cip-CoA, pre-
applied for 15 s, followed by its co-application with ATP. The same
oocyte was used to compare an ATP concentration^response curve in
the absence and later in the presence of CoA derivatives. Separate
protocols established the selectivity of the receptor blockade in the
presence of 10 WM CoA-SH or 10 WM Cip-CoA in P2Y2, P2X2, P2X4,
5-HT2A or 5-HT2C receptors, challenged in each case with the median
e¡ective concentration of each ligand. Non-parametric statistical anal-
ysis was performed.
Curves were normalized against 10 WM ATP, using the GraphPad
‘Prism’ program (GraphPad Software, San Diego, CA, USA). From
the corresponding Schild plots, pA2 values and their 3log(KB) were
calculated by regression analysis; the slope of the plots was also
estimated. The Kruskal^Wallis test [14] was used as a non-parametric
test for statistical analysis; the Student t-test for multiple comparisons
to a common control (Dunnett’s tables) was also used when appro-
priate.
2.4. Determination of the octanol/bu¡er partition coe⁄cients
To assess the in£uence of hydrophobicity on the antagonist potency
of the compounds tested, the partition coe⁄cients based on the rela-
tive solubility of nafenopin, cipro¢brate, palmitic acid, and acetate in
octanol and Barth’s bu¡er were determined. Since the CoA moiety
makes the drug more hydrophilic, and because we were particularly
interested in the contribution of the bulkiness/hydrophobicity of the
drug to the CoA antagonism, we compared the partition coe⁄cients
of the drugs in their non-metabolized form. For this purpose, 30 Wg of
cipro¢brate or nafenopin was dissolved in methanol and mixed in
equal parts of octanol and bu¡er to determine their concentrations
in the organic and the aqueous phase. After thorough mixing, an
aliquot of each phase was injected into a C18 chromatographic column
and eluted isocratically with methanol/H2O in 20 mM KH2PO4 bu¡er
(pH=5.5). This procedure allows the analytical separation and detec-
tion of the ¢brates in either phase. Control protocols established the
linearity of the procedure and optimized the conditions for chromato-
graphic drug quanti¢cations. Likewise, the partition coe⁄cient of
acetate and palmitate was determined using a similar procedure except
that 14C-labeled standards were used; radioactivity was measured in
each phase by dissolving an aliquot of each phase in a standard
scintillation bu¡er. Based on these data, the partition coe⁄cients
were calculated.
3. Results
3.1. CoA-SH antagonized the currents evoked by ATP in
P2Y1 receptors
CoA-SH blocked in a reversible and concentration-depen-
dent manner the current gated by 0.2 WM ATP, a value close
to the ligand median e¡ective concentration. The IC50 for
CoA-SH was 0.93O 0.17 WM (n=4, Fig. 1 and Table 1); the
sole application of up to 10 WM CoA-SH, in the absence of
ATP, did not elicit detectable currents (Fig. 1). MRS 2179, a
3P,5P-bisphosphate purine analog with recognized selectivity
Fig. 1. Antagonism by CoA-related compounds. A: Representative
tracings. Neither CoA-SH nor nafenopin-CoA (Na-CoA) evoked
any response when applied to an oocyte expressing the P2Y1 recep-
tor, but they inhibited the ATP-evoked currents when pre-applied
and then co-applied with the agonist. This e¡ect was not mimicked
by nafenopin. These recordings represent calcium-activated chloride
currents used as an indicator of nucleotide receptor activity. B: A
collection of data showing antagonism induced by CoA-SH (¢lled
circles), nafenopin-CoA (¢lled squares), and palmitoyl-CoA (open
circles) in at least four di¡erent oocytes expressing the P2Y1 recep-
tor.
Table 1
Antagonism of acyl-CoAs and related compounds over the P2Y1
receptor
Drug IC50, WM (xOS.E.M.) n
CoA-SH 0.93O 0.17 4
Nafenopin-CoA 0.07O 0.01** 4
Nafenopin s 100 4
Cipro¢broyl-CoA 0.34O 0.05* 5
Cipro¢brate s 100 4
Palmitoyl-CoA 0.23O 0.07** 4
Palmitoyl-carnitine s 100 4
Acetyl-CoA 1.38O 0.57 3
Acetyl-carnitine s 100 4
MRS 2179 0.020O 0.018** 4
Oocytes were challenged with 0.2 WM ATP. The compounds were
pre-applied for 15 s and then co-applied together with ATP.
*P6 0.05; **P6 0.01, as compared to the IC50 of CoA-SH
(Kruskal^Wallis and Dunnett’s t-test).
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for the P2Y1 receptor, had an IC50 almost 50-fold lower (Ta-
ble 1). Increasing the duration of the CoA-SH pre-application
from 15 to 30 or 60 s did not further increase the magnitude
of the inhibition (data not shown), suggesting that within 15 s
the interaction had reached equilibrium.
3.2. Potency and nature of the nafenopin-CoA and cipro¢broyl-
CoA-induced P2Y1 receptor antagonism
While Naf-CoA was 13-fold more potent than CoA-SH
(Fig. 1), Cip-CoA was only three-fold more active than
CoA-SH to block the current evoked by 0.2 WM ATP (Table
1). Neither 100 WM nafenopin nor cipro¢brate altered the
ATP-evoked currents (see tracings in Fig. 1 and Table 1).
Naf-CoA and Cip-CoA displaced rightwards, and in a parallel
manner, the ATP concentration^response curves (Fig. 2),
compatible with competitive antagonism. Neither drug-CoAs
reduced the maximal ATP-evoked currents except for the larg-
est concentrations of ATP following 1 WM Naf-CoA. The
estimated KBs for Naf-CoA and Cip-CoA were 58 and 148
nM, respectively. Con¢rming the competitive nature of the
antagonism, the slopes of the corresponding Schild plots
were 0.89 and 1.01, respectively.
3.3. Endogenous acyl-CoAs
Acetyl-CoA and palmitoyl-CoA also antagonized the ATP-
evoked currents in a reversible fashion (Fig. 1B and Table 1).
Acetylating CoA-SH did not modify its relative potency in a
signi¢cant manner, but palmitoyl-CoA was four times more
potent than CoA-SH. 100 WM acetyl or palmitoyl-carnitine
were inactive, con¢rming the importance of the CoA-moiety
for the antagonist interaction (Table 1).
3.4. Relationship between partition coe⁄cient and
CoA-derivative potency
The octanol/bu¡er partition coe⁄cient of nafenopin was
about 10-fold larger than that of cipro¢brate, and 10 times
lower than that of palmitate (Fig. 3, inset). A linear relation-
ship was found between the partition coe⁄cients of acetate,
cipro¢brate, and nafenopin and the relative potency of their
respective CoA-SH derivatives (r=0.99, P6 0.05, Fig. 3). Pal-
mitate did not follow this linear relationship, indicating that
additional factors besides hydrophobicity are important for
the interaction with the receptor.
3.5. Subtype selectivity and receptor speci¢city of drug-CoAs
All the acyl-CoAs examined, including CoA-SH, showed
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Fig. 2. Nafenopin-CoA and cipro¢broyl-CoA are competitive antag-
onists of the P2Y1 receptor. A: Concentration^response curves for
ATP alone (¢lled circles) or plus 0.1, 0.3 and 1 WM of nafenopin-
CoA (Naf-CoA); the inset shows the Schild plot for these experi-
ments. Naf-CoA was pre-applied for 15 s and then co-applied with
ATP, n=4. B: Concentration^response curves of ATP in the ab-
sence (¢lled circles) and in the presence of 0.3 (open squares),
1 (¢lled triangles) and 5 (open triangles) WM of cipro¢broyl-CoA
(Cip-CoA); the inset shows the Schild plot for these curves. Cip-
CoA was pre-applied and then co-applied with ATP, n=4.
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Fig. 3. Octanol/bu¡er partition coe⁄cients. The relative antagonist
potency of acetyl-CoA (Ac-CoA), cipro¢broyl-CoA (Cip-CoA), pal-
mitoyl-CoA (Pal-CoA) and nafenopin-CoA (Naf-CoA) was plotted
against the octanol/bu¡er partition of their hydrophobic substituents
shown in the inset (Ac, acetate; Cip, cipro¢brate; Naf, nafenopin;
Pal, palmitate).
Table 2
Speci¢city of antagonism induced by CoA-SH and cipro¢broyl-CoA
Receptor Control Percentage of response
+10 WM CoA-SH +10 WM Cip-CoA
P2Y1 100O 2.2 (27) 15.8O 4.0* (4) 3.1 O 1.9* (4)
P2Y2 100O 2.3 (19) 104.8O 7.6 (4) 107.5O 13.3 (4)
P2X2 100O 3.7 (9) 104.3O 12.2 (4) 99.4O 7.0 (4)
P2X4 100O 1.0 (6) 106.2O 3.6 (4) 105.4O 1.5 (4)
5-HT2A 100O 1.1 (8) 96.2O 5.0 (4) 91.9O 18.0 (3)
5-HT2C 100O 8.5 (4) 101.2O 7.9 (3) 101.5O 7.5 (4)
Values are meanOS.E.M.; the number of experiments is indicated
in brackets. CoA-SH and cipro¢broyl-CoA (Cip-CoA) were pre-
applied for 15 s and then co-applied with the agonist in all cases.
Agonists used: 0.2 WM ATP for P2Y1 receptors; 3 WM ATP for
P2Y2 receptors; 30 WM ATP for P2X2 receptors; 10 WM ATP for
P2X4 receptors; 0.1 WM 5-HT for 5-HT2A receptors and 0.01 WM
5-HT for 5-HT2C receptors. *P6 0.001, as compared with the cur-
rents obtained with ATP alone (Kruskal^Wallis test).
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receptor speci¢city for the P2Y1 receptor subtype. None of
them reduced the currents elicited by ATP acting on P2Y2
receptors (Fig. 4), nor on the P2X2 and P2X4 receptors (Table
2). Furthermore, neither 10 WM CoA-SH nor Cip-CoA antag-
onized 5-HT responses in 5-HT2A or 5-HT2C receptors, which,
like the P2Y1 receptor, are coupled to the Gq11 protein (Table
2).
4. Discussion
The present study clearly demonstrates that CoA-SH, fatty
acyl-CoA derivatives and ¢brate-CoAs are reversible, selec-
tive, and competitive antagonists of the human P2Y1 receptor.
To understand the mechanism of the antagonism elicited by
CoA-SH and its derivatives, it is necessary to observe the
structural similarity between the 3P,5P-nucleotide moiety of
CoA-SH and ADP/ATP. In our interpretation, the structures
hint at a possible interaction of the CoA-SH moiety with the
P2Y1 receptor ligand-binding site. The increased potency of
the fatty acyl-CoAs, as observed with palmitoyl-CoA, may be
due to an interaction at a hydrophobic pocket close to the
ligand-binding domain. We now identify that a bulky hydro-
phobic extension in the CoA-SH moiety, as present in Naf-
CoA, further increases the antagonist potency of CoA-SH. A
possible interpretation for this ¢nding is that Naf-CoA and
the other lipophilic CoA derivatives tested interact with two
distinct sites on the receptor. One site would correspond to
the purine binding site, which seems to involve several amino
acids of the transmembrane domains 3, 6, 7 [15] and charged
amino acids that are part of the extracellular loops 2 and 3
[16]. The second site would be a hydrophobic pocket in the
vicinity of the purine site, which would involve hydrophobic
amino acid residues to accommodate the lipophilic acyl-sub-
stituent. This pocket would help stabilize the interaction of
the antagonist to the receptor, but its occupation would not
elicit a response per se. Consonant with this interpretation,
neither nafenopin, cipro¢brate, acetyl-carnitine, nor palmi-
toyl-carnitine have a P2Y1 receptor antagonist pro¢le.
Even though palmitoyl-CoA and Cip-CoA have similar
IC50s, palmitate is 100-fold more hydrophobic than cipro¢-
brate. Despite the greater hydrophobicity of palmitate, the
£exibility of its aliphatic chain might explain the lesser po-
tency than expected solely from the hydrophobicity analyses.
The advantage of determining relative hydrophobicity using
the intact compound and not the CoA derivative is the higher
resolution, since the more soluble CoA derivatives do not
allow us to establish the hydrophobic contribution of each
compound. The results with palmitate suggest that while hy-
drophobicity is important for the added antagonism potency,
perhaps bulkiness also plays a critical role. Therefore it is
plausible that Naf-CoA, which is bulkier than Cip-CoA and
palmitoyl-CoA, accommodates better into this putative hy-
drophobic pocket. By the same argument, the addition of
only two carbons to CoA-SH, as in acetyl-CoA, does not
increase the potency of the parent compound, con¢rming
the importance of bulk and hydrophobicity for the increase
in the antagonist potency.
MRS 2179 is a selective competitive antagonist for the
P2Y1 receptor [17,10] ; its potency to antagonize the human
P2Y1 receptor agrees with the report of Buvinic et al. [10], but
is somewhat di¡erent from that described in turkey erythro-
cytes [17], a ¢nding which could re£ect species and methodo-
logical variations. Considering the structural similarity of
MRS 2179 to the endogenous ligands of the P2Y1 receptor,
and the lack of a hydrophobic side chain, it is probable that
MRS 2179 binds exclusively to the purine-binding site, as is
probably the case for the recently developed MRS 2279, a
new and more potent 3P5P-bisphosphate purine analog with
P2Y1 antagonist properties [18]. This interpretation reinforces
the idea that the hydrophobic substituents of CoA derivatives
bind to an additional pocket in the vicinity of the nucleotide
binding site and that their major e¡ect is to stabilize the in-
teraction of the CoA moiety to the receptor. By the same
argument, the adenosine-5P-carboxylic acid derivatives (Ado-
CAsp conjugates) are considerably less potent as P2Y1 antag-
onists than the hypolipidemic drug-acyl-CoAs described in
this communication, since they lack phosphate groups a¡ect-
ing their a⁄nity for the purine binding site, and a hydropho-
bic side chain to stabilize the interaction [19]. Along the same
lines, Boyer et al. [20] showed that the potency of saturated
fatty acyl-CoAs as P2Y1 receptor antagonists increases almost
100-fold with chain length, reaching a cuto¡ at C12. These
results are consonant with our ¢nding that the length of the
fatty acid chain contributes to hydrophobicity but requires
bulkiness as well to reach a higher potency. Di¡erences in
the inhibitory potency of CoA-SH or the endogenous acyl-
CoAs examined were found compared to those of Boyer et al.
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Fig. 4. Selective P2Y1 receptor antagonism induced by drug-CoAs
and palmitoyl-CoA. A: Representative tracings of an oocyte ex-
pressing the P2Y2 receptor and the e¡ects of CoA-SH, nafenopin-
CoA (Naf-CoA), cipro¢broyl-CoA (Cip-CoA) and palmitoyl-CoA
(Pal-CoA). B: Comparison of the e¡ects induced by these com-
pounds in P2Y1 (¢lled bars) and P2Y2 receptors (open bars). 10 WM
of CoA derivatives was pre-applied for 15 s and then co-applied
with 0.2 WM ATP for P2Y1 receptors and 3 WM ATP for P2Y2 re-
ceptors, with the exception of Naf-CoA in P2Y1 receptors; in this
case 3 WM Naf-CoA induced a complete inhibition of the ATP-
evoked response. Bars represent meanOS.E.M. of at least four sepa-
rate oocytes.
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[20] ; these discrepancies might be related in part to di¡erential
levels of receptor expression, the intracellular messenger de-
termined and/or in part to di¡erences between the human and
the turkey receptor. Boyer et al. [20] reported that CoA-SH
behaved as a partial agonist at mM concentrations; in our
study 100 WM was inactive and larger concentrations were not
tested.
The speci¢city of drug action is accounted for by the ¢nd-
ing that none of the CoA derivatives interact with the ATP
binding site in the P2X receptors, which are ionic channels,
and are therefore structurally unrelated to the P2Y receptor
family. Experiments with 5-HT2 receptors indicate that these
compounds probably interact with the P2Y1 protein, and not
with the signaling pathway, since both the P2Y1 and the
5-HT2 receptors are coupled to Gq11 and activate a Ca2þ-
dependent chloride channel. Since one of the endogenous
ligands of the P2Y2 receptor is a pyrimidine [7], it is possible
that CoA-SH or acyl-CoA derivatives do not have su⁄cient
a⁄nity for the pyrimidine/purine binding site, and are there-
fore inactive, explaining the lack of response in these recep-
tors.
The issue of the physiological ligand of the P2Y1 receptor is
a matter of debate. Some authors argue that ADP rather than
ATP is the endogenous ligand [21^23], while other investiga-
tors have shown that ATP antagonizes the P2Y1 receptor,
particularly in platelets [11,24]. In our oocyte studies, ATP
behaves as an agonist with a median e¡ective concentration
of 156O 18 nM (n=10). To avoid ATP degradation, we used
freshly prepared ATP solutions; HPLC analysis showed no
detectable ADP contamination (data not shown). The 10-s
ATP application reduces the possibility of its degradation to
ADP.
Although it is highly unlikely to ¢nd high levels of extra-
cellular CoA-¢brates or fatty acid CoAs due to the abundance
of plasma lipases, we are aware that in pathophysiological
conditions such as hypoxia, heart ischemia or the presence
of necrotic tissue, there is a massive release of intracellular
acyl-carnitines from the kidney or the liver [25,26], an indica-
tion that intracellularly stored lipids might be released to the
plasma. At present there are no determinations of acyl-CoAs,
including the ¢brate-CoAs in extracellular £uids (Bar-Tana,
personal communication). However, during ischemia, consid-
erable changes in heart and brain acyl-CoAs occur [27,28],
making it interesting to study the potential role of these en-
dogenous compounds as P2Y1 antagonists during these
events. Likewise, fatty acyl-CoAs enhanced glutamate release
from rat hippocampal slices [29], a datum that suggests that
brain acyl-CoAs may play a role in neuronal plasticity, such
as in long-term potentiation. Furthermore, chronic treatment
with clo¢brate, another clinically used ¢brate [30,31], caused
platelet aggregation de¢ciencies, a process in which the P2Y1
receptor seems to play a relevant role [32]. In light of this
¢nding, and keeping in mind that human platelets express
the P2Y1 receptor [11] and metabolize drugs to CoA deriva-
tives [2], the present results might have clinical relevance. Ad-
ditionally, ¢brates may also a¡ect coagulation by inhibiting
hepatic ¢brinogen synthesis, an e¡ect mediated by PPARK
[33].
These results may lead to the search of putative long-chain
fatty acyl-CoAs as possible endogenous modulators of the
P2Y1 receptor, compounds which may mimic the action of
these ¢brate-CoAs. This hypothesis might o¡er novel avenues
of clinically relevant research. Independent of the clinical rele-
vance of these ¢brate metabolites, drug acyl-CoAs, such as
Naf-CoA, might be a promising lead to develop novel nucle-
otide receptor tools, which may help to identify for example
the ATP binding pocket or the site of action of putative en-
dogenous modulators.
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